Company: APM
Filing Date: 2025-07-22
Form Type: 6-K
Source: 0001213900-25-066642
Chunk: 12

Company: Aptorum Group Ltd
Filing Date: 2025-07-22
Form: 6-K
Chunk 12
---
 by written notice from DiamiR to Aptorum, if Aptorum fails to obtain                                                                    
 its shareholders approval upon vote taken thereon at a duly convened Special Meeting (or at a meeting of its shareholders following any 
 adjournment or postponement thereof);                                                                                                   |

| ● | by written notice from Aptorum or DiamiR to the other, if                        
 the closing shall not have been consummated on or prior to the Termination Date; |

<div align='center'>7</div>

For purposes of the Merger
Agreement, “” means December 31, 2025; provided that the Termination Date may be extended if expressly
so agreed in writing by Aptorum and DiamiR.

In the event that, the Merger Agreement is terminated for reasons other
than DiamiR’s breach or failure to perform, and that Aptorum has raised capital by issuance of its equity securities during the
Interim Period (as defined in the Merger Agreement included hereto as Exhibit 2.1), Aptorum agrees to pay in cash to DiamiR, a fee in
the amount equal to the higher of (i) 70% of cash that Aptorum has as of the date of Termination, and (ii) $2,000,000 (the “Termination
Fee”). In the event that the Merger Agreement is terminated and that Aptorum has not raised capital by issuance of its equity securities
during the Interim Period, each party agrees to bear its own expenses incurred with the Merger and the related transactions.

Management Services Agreement

At the time of the execution
of the Merger Agreement, Aptorum Therapeutics, and DiamiR entered into a management services agreement pursuant to which Aptorum Therapeutics
shall pay a monthly service fee and reimburse expenses to DiamiR in exchange for the officers and employees of DiamiR providing services
to Aptorum Therapeutics to develop a diagnostic test for early detection and monitoring of progression of glioblastoma until the earlier
of the closing of the Merger or December 31, 2025 in the following positions, subject to change as set forth in the agreement: Alidad
Mireskandari, President or CEO; Gary Anthony, Comptroller or CFO; Gyanendra Kumar, V.P. of Assay Development; Kenny Ablordeppey,
Director of Assay Development; Jacob Goldman, Data Scientist; and Sydney Finkelstein, Medical Director.

Intellectual Property License Agreement